Seav Susan M, Dominick Sally A, Stepanyuk Boris, Gorman Jessica R, Chingos Diana T, Ehren Jennifer L, Krychman Michael L, Su H Irene
1Department of Reproductive Medicine and Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Dive #0901, La Jolla, CA 92093 USA.
2Young Survival Coalition, 80 Broad Street, New York, NY 10004 USA.
Womens Midlife Health. 2015 Nov 2;1:9. doi: 10.1186/s40695-015-0009-4. eCollection 2015.
Female sexual dysfunction occurs frequently in midlife breast cancer survivors (BCS) and encompasses problems with sexual desire, interest, arousal, orgasm and genitopelvic pain. Although common, sexual problems are under-diagnosed and under-treated in BCS. The objective of this review was to assess primary studies that intervene on sexual dysfunction in BCS. In February 2015, PubMed, SCOPUS, CINAHL, COCHRANE and Web of Science databases were systematically searched for randomized controlled clinical trials (RCTs) of vaginal (lubricants, moisturizers, estrogens, dehydroepiandrosterone [DHEA], testosterone, vibrators, dilators), systemic (androgens, anti-depressants, flibanserin, ospemifene), physical therapy (physical activity, pelvic floor training), counseling and educational interventions on sexual function in BCS. Observational studies of vaginal interventions were also included due to the paucity of RCTs. The search yielded 1414 studies, 34 of which met inclusion criteria. Both interventions and outcomes, measured by 31 different sexual function scales, were heterogeneous, and therefore data were not pooled. The review found that regular and prolonged use of vaginal moisturizers was effective in improving vaginal dryness, dyspareunia, and sexual satisfaction. Educational and counseling interventions targeting sexual dysfunction showed consistent improvement in various aspects of sexual health. No consistent improvements in sexual health were observed with physical activity, transdermal testosterone or hot flash interventions. There was a lack of BCS-specific data on vaginal lubricants, vibrators, dilators, pelvic floor therapy, flibanserin or ospemifene. Overall, the quality of evidence for these studies was moderate to very low. Because each of the interventions with BCS data had limited efficacy, clinical trials to test novel interventions are needed to provide evidence-based clinical recommendations and improve sexual function in BCS.
女性性功能障碍在中年乳腺癌幸存者(BCS)中频繁出现,包括性欲、性兴趣、性唤起、性高潮和生殖器盆腔疼痛等问题。尽管很常见,但BCS中的性问题诊断不足且治疗不足。本综述的目的是评估干预BCS性功能障碍的原始研究。2015年2月,对PubMed、SCOPUS、CINAHL、COCHRANE和科学网数据库进行了系统检索,以查找关于阴道(润滑剂、保湿剂、雌激素、脱氢表雄酮[DHEA]、睾酮、振动器、扩张器)、全身(雄激素、抗抑郁药、氟班色林、奥培米芬)、物理治疗(体育活动、盆底训练)、咨询和教育干预对BCS性功能影响的随机对照临床试验(RCT)。由于RCT数量稀少,阴道干预的观察性研究也被纳入。检索共获得1414项研究,其中34项符合纳入标准。干预措施和由31种不同性功能量表测量的结果均存在异质性,因此未进行数据合并。该综述发现,定期长期使用阴道保湿剂可有效改善阴道干燥、性交困难和性满意度。针对性功能障碍的教育和咨询干预在性健康的各个方面均显示出持续改善。体育活动、经皮睾酮或潮热干预未观察到性健康的持续改善。关于阴道润滑剂、振动器、扩张器、盆底治疗、氟班色林或奥培米芬,缺乏针对BCS的特定数据。总体而言,这些研究的证据质量为中等至非常低。由于每项有BCS数据的干预措施疗效有限,需要进行临床试验以测试新的干预措施,从而提供基于证据的临床建议并改善BCS的性功能。